Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback